CompletedPhase 2

A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy

Denmark, Germany22 participantsStarted 2017-06-07

Plain-language summary

The objectives of this trial are safety and efficacy (proof-of-concept) of induction of mucosal healing by BI 655130 add-on therapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activity despite pre-existing TNFi treatment. This trial will explore safety and efficacy of a dose of BI 655130 that was modelled to achieve the similar exposures as the highest exposures tested and found safe and tolerable in preceding single and multiple dose studies in healthy subjects, as add-on to pre-existing TNFi (Tumor necrosis factor inhibitor) treatment. Secondary and further objectives include assessment of the pharmacokinetic (PK) profile of BI 655130 and early exploration of specific biomarkers with potential usefulness to predict clinical efficacy or safety outcome or help understand BI 655130's mode of action.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * 18 - 75 years at screening and randomisation * Diagnosis of ulcerative colitis \>= 5 months prior to screening * Receiving TNFi treatment with doses (i.e. dose and dosing interval) unchanged for \>= 4 months (Infliximab) or \>= 2 Monaten (Adalimumab or Golimumab) prior to randomisation * Mild or moderate disease activity, defined as total Mayo Score (MCS) (\<= 10) * Further inclusion criteria apply Exclusion Criteria: * Prior use of more than two different TNF inhibitors or vedolizumab * Extensive colonic resection * Evidence of infection with C. difficile or other intestinal pathogen \<28 days prior to screening * Active or latent tuberculosis * Further exclusion criteria apply

What they're measuring

Proportion of Participants With Endoscopic Improvement (MCS mESS ≤1) at Week 12

Timeframe: At Week 12

Trial details

NCT IDNCT03123120

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-03-26

Results submitted2021-09-15